Butenafine HCl 1% (BAY1896425)

Phase 3Completed
0 watching 0 views this week๐Ÿ“ˆ Rising
74
Hype Score

Development Stage

โœ“
Pre-clinical
โœ“
Phase 1
โœ“
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Dermatitis, Phototoxic

Conditions

Dermatitis, Phototoxic

Trial Timeline

Jun 24, 2013 โ†’ Jun 28, 2013

About Butenafine HCl 1% (BAY1896425)

Butenafine HCl 1% (BAY1896425) is a phase 3 stage product being developed by Bayer for Dermatitis, Phototoxic. The current trial status is completed. This product is registered under clinical trial identifier NCT04531527. Target conditions include Dermatitis, Phototoxic.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04531540Phase 3Completed
NCT04531527Phase 3Completed

Competing Products

20 competing products in Dermatitis, Phototoxic

See all competitors
ProductCompanyStageHype Score
LebrikizumabEli LillyPhase 3
77
Baricitinib + Placebo + Topical corticosteroidEli LillyPhase 3
77
LebrikizumabEli LillyApproved
85
LebrikizumabEli LillyPhase 3
77
Lebrikizumab + PlaceboEli LillyPhase 3
77
BioLexa- Cohort 1 + BioLexa- Cohort 2 + Placebo + GentamicinHoth TherapeuticsPhase 1
25
LebrikizumabEli LillyPhase 3
77
ASN008Formation BioPhase 2
44
ENS-002Concerto BiosciencesPhase 1
25
nemolizumab (CIM331)Chugai PharmaceuticalPhase 2
52
DS-2741a + PlaceboDaiichi SankyoPhase 1
33
SUN13834 + PlaceboDaiichi SankyoPhase 2
52
5 mg ASB17061 + Placebo + 10 mg ASB17061 + 20 mg ASB17061Daiichi SankyoPhase 2
52
Tacrolimus Ointment 0.03% + Tacrolimus Ointment 0.03%Astellas PharmaPhase 2
52
tacrolimus ointmentAstellas PharmaPhase 3
77
tacrolimus 0.1% + fluticasone 0.005 %Astellas PharmaApproved
85
tacrolimus ointment + pimecrolimus creamAstellas PharmaApproved
85
tacrolimus ointment 0.03% + hydrocortisone acetate ointment 1% + hydrocortisone butyrate ointment 0.1% + Meningitec + AC VAXAstellas PharmaPhase 2
52
tacrolimusAstellas PharmaApproved
85
Tacrolimus Ointment 0.1%Astellas PharmaPhase 2
52